Department of Pharmacology, School of Pharmacy, Nantong University, Nantong 226001, Jiangsu, China.
Department of Orthopaedics, Affiliated Hospital 2 of Nantong University, Nantong 226001, Jiangsu, China.
Biochem Pharmacol. 2022 Jan;195:114836. doi: 10.1016/j.bcp.2021.114836. Epub 2021 Nov 11.
Depression is one of the most common psychiatric diseases in the 21st century, while its pathogenesis is not yet fully understood. Currently, besides to the monoaminergic system, the brain-derived neurotrophic factor (BDNF)-cAMP response element-binding protein (CREB) signaling is one of the most attractive signaling pathways for treating depression. Mitogen and stress-activated kinase (MSK) 1 and 2 are nuclear proteins activated downstream of the ERK1/2 or p38 MAPK pathways, and it has been demonstrated that MSKs are involved in the BDNF-CREB signaling. Here we assumed that MSKs may play a role in depression, and various methods including the chronic social defeat stress (CSDS) model of depression, western blotting, immunofluorescence and virus-mediated gene transfer were used together. It was found that CSDS fully enhanced the expression of both phosphorylated MSK1 and total MSK1 in the hippocampus but not the medial prefrontal cortex (mPFC). CSDS did not influence the expression of phosphorylated MSK2 and total MSK2 in the two brain regions. Genetic over-expression of hippocampal MSK1 fully prevented not only the CSDS-induced depressive-like behaviors but also the CSDS-induced dysfunction in the hippocampal BDNF-CREB signaling and neurogenesis in mice, while genetic knockdown of hippocampal MSK1 aggravated the CSDS-induced depressive-like symptomatology in mice. Our results collectively suggest that although CSDS evidently enhances the activity of hippocampal MSK1, it is not a contributor to the CSDS-induced dysfunction in the brain but a defensive feedback regulator which protects against CSDS. Therefore, hippocampal MSK1 participates in the pathogenesis of depression and is a feasible and potential antidepressant target.
抑郁症是 21 世纪最常见的精神疾病之一,但其发病机制尚未完全阐明。目前,除了单胺能系统外,脑源性神经营养因子(BDNF)-cAMP 反应元件结合蛋白(CREB)信号通路是治疗抑郁症最有吸引力的信号通路之一。丝裂原和应激激活激酶(MSK)1 和 2 是 ERK1/2 或 p38 MAPK 通路下游激活的核蛋白,已证明 MSKs 参与 BDNF-CREB 信号通路。在这里,我们假设 MSKs 可能在抑郁症中发挥作用,同时使用了包括慢性社会挫败应激(CSDS)抑郁症模型、western blot、免疫荧光和病毒介导的基因转移等各种方法。结果发现 CSDS 完全增强了海马体中磷酸化 MSK1 和总 MSK1 的表达,但对内侧前额叶皮质(mPFC)中的表达没有影响。CSDS 对两个脑区中磷酸化 MSK2 和总 MSK2 的表达没有影响。海马体 MSK1 的基因过表达完全阻止了 CSDS 诱导的抑郁样行为,以及 CSDS 诱导的海马体 BDNF-CREB 信号和神经发生功能障碍,而海马体 MSK1 的基因敲低则加重了 CSDS 诱导的抑郁样症状。我们的研究结果表明,尽管 CSDS 明显增强了海马体 MSK1 的活性,但它不是 CSDS 诱导的脑功能障碍的原因,而是一种防御性的反馈调节因子,可防止 CSDS 的影响。因此,海马体 MSK1 参与了抑郁症的发病机制,是一种可行的、有潜力的抗抑郁靶点。